• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®


 Dates for financial information and other events
September 28 − October 1, 2021
EASD 2021
57th Annual Meeting, virtual event
October 6, 2021
Year-End Report
Year-End Report 2020/2021
December 2, 2021
Annual General Meeting
Annual General Meeting 2020/2021

Company Presentation

 June 23, 2021

The findings and the publication in Diabetes Care strongly support the diabetes vaccines’s efficacy in preserving beta cell function in individuals carrying the DR3-DQ2 genes.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3, 20/21


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research